The receptor-specific monoclonal antibodies bevacizumab [4, 5] and cetuximab [6] have shown remarkable outcome in vascular growth factor receptor- (VEGF-) positive and epidermal growth factor receptor (EGFR)-positive cancer, respectively. The gene discussed is EGFR; the disease is cancer.